Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Inhibikase Therapeutics (Nasdaq: IKT) granted non-qualified stock options for an aggregate of 685,718 shares to five newly hired non-executive employees under its 2026 Inducement Equity Plan, effective March 31, 2026. The options carry a $1.68 exercise price, equal to the closing price on the effective date.

The awards have a 10-year term, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments. Grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).

Market Context

This announcement details routine equity-based hiring incentives, granting 685,718 non-qualified sto...

Analysis

This announcement details routine equity-based hiring incentives, granting 685,718 non-qualified stock options at an exercise price of $1.68 under the 2026 Inducement Equity Plan. The options carry a 10-year term with 25% vesting after one year and the remainder over 36 months, aligning new employees with long-term performance. In context of Inhibikase’s ongoing pivotal PAH program and prior capital raises, investors may watch how staffing and compensation support execution of clinical and regulatory milestones.

Key Figures

Inducement options granted: 685,718 options Employees receiving grants: 5 employees Exercise price: $1.68 per share +3 more

6 metrics

Inducement options granted 685,718 options Non-qualified stock options to newly hired non-executive employees

Employees receiving grants 5 employees Newly hired non-executive staff under 2026 Inducement Equity Plan

Exercise price $1.68 per share Equal to common stock closing price on March 31, 2026

Option term 10 years Ten-year term for inducement stock options

Initial vesting tranche 25% Vests on first anniversary of March 31, 2026 Effective Date

Remaining vesting 75% over 36 months Vests in 36 equal monthly installments after first anniversary

Historical Context

5 past events · Latest: Mar 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 26	Full-year earnings	Positive	+3.1%	Reported 2025 results, strong cash of $178.8M and key Phase 3 progress.
Nov 20	Offering priced	Negative	-2.6%	Priced $100M offering of common stock and pre-funded warrants.
Nov 20	Offering proposed	Negative	-2.6%	Proposed underwritten offering from existing Form S-3 shelf registration.
Nov 20	Phase 3 trial plan	Positive	-2.6%	Announced plan to initiate global pivotal Phase 3 IKT-001 PAH trial.
Nov 14	Q3 earnings	Neutral	-0.7%	Reported Q3 2025 results and outlined upcoming Phase 2b PAH trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offerings and financing announcements have previously seen negative price reactions, while earnings and major trial updates have produced mixed follow-through, including at least one divergence where positive clinical news coincided with a decline.

Recent Company History

Over the past six months, Inhibikase has balanced financing, clinical, and financial updates. In November 2025, it advanced IKT‑001 toward a global Phase 3 PAH trial and announced both proposed and priced equity offerings, which saw modest declines. Earnings releases in Q3 2025 and full-year 2025 highlighted growing R&D investment and cash from a large public offering. Today’s inducement option grants under Nasdaq Listing Rule 5635(c)(4) fit into this broader picture of building the team to support ongoing Phase 3 execution.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, inducement equity plan

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

inducement equity plan financial

"under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026"

An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 685,718 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of March 31, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.68 per share, which is equal to the closing price of the Company’s common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

FAQ

What did Inhibikase Therapeutics (IKT) announce on April 3, 2026 about stock option grants?

They granted options covering 685,718 shares to five new non-executive hires. According to the company, grants are effective March 31, 2026 with an exercise price of $1.68, equal to the closing price on that date.

What are the exercise price and term for the IKT inducement options granted March 31, 2026?

The options have an exercise price of $1.68 and a 10-year term. According to the company, $1.68 equals the common stock closing price on the effective date and options expire after ten years.

How do the vesting terms for the IKT March 31, 2026 inducement grants work?

Vesting is 25% after one year, then 75% in 36 equal monthly installments. According to the company, this schedule applies to the options granted under the 2026 Inducement Equity Plan.

Why did Inhibikase (IKT) issue these stock options under Nasdaq Listing Rule 5635(c)(4)?

They were issued as material inducements to new employees to join the company. According to the company, the Compensation Committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).

Will the IKT inducement option grants cause immediate dilution for existing shareholders?

The announcement does not state a percentage dilution impact. According to the company, 685,718 options were granted, but total outstanding share count is not provided to calculate dilution.